

DILON DIAGNOSTICS FACT SHEET

The Company: Dilon Diagnostics, located in Newport News, Va., designs, manufactures and commercializes innovative medical imaging products worldwide based on cooperative research and development with the Department of Energy's Thomas Jefferson National Accelerator Facility, located in Newport News, Va. The company's mission is to deliver leading edge molecular imaging products and services along with strategic alliances that provide advanced tools for early cancer diagnostics.

Products & Services: The Dilon 6800 Gamma Camera, Dilon's cornerstone product, is a high-resolution, small field-of-view gamma camera optimized to perform Breast-Specific Gamma Imaging (BSGI). BSGI is a molecular breast imaging procedure that aids in the effective management of suspicious and difficult-to-interpret breast cases. The Dilon 6800 captures vital information by viewing the metabolic activity in the breast; it can identify lesions independent of tissue density and is capable of duplicating standard mammographic views. Because of its small size and portability, the Dilon 6800 can be used in the breast-imaging center, allowing for same-day evaluation at the point of care. The Dilon 6800 also serves a broader utility in general nuclear medicine applications including, but not limited to thyroid imaging and spot bone scans.

Additionally, Dilon's new products and technology/service alliances support its comprehensive, efficient diagnostic regimen, such as:

- The Dilon 6800 Access ~ mobile camera system
- The GammaLoc® (Pending 510K Clearance) ~ Gamma-guidance localization to enable biopsy
- Nuclear Medicine Accreditation and Licensing services
- Terason t3000 Laptop Ultrasound System
- PenRad Mammography Information System

BSGI Procedure: BSGI is an adjunctive molecular breast imaging technique to mammography, ultrasound and MRI that can discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding breast tissue and generally appear as "hot spots" on the BSGI image. In addition, BSGI has very high sensitivity for identifying earlier stage cancers — as small as 1 mm in clinical studies; and with a Negative Predictive Value (NPV) comparable to MRI.

The Experience: After more than 10 years of development and clinical implementation, the Dilon 6800 Gamma Camera has been instrumental in finding hard-to-detect lesions that other imaging modalities may miss, such as lobular carcinoma and Ductal Carcinoma In situ (DCIS). Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information, visit www.dilon.com or call 877-GODILON.